Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Thomas Koroscil

Hospitalist Dayton, OH Medical Doctor

NPI 1588058408 CMS profile 2785623

128 E Apple St, 2Nd Floor, Dayton, OH 45409

Open in the dashboard

General payments

$4,005

88 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Thomas Koroscil of Dayton, OH is reported in the CMS Open Payments database as having received $4,005 across 88 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Hospitalist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $261 8
2022 General $587 15
2021 General $1,196 36
2020 General $433 11
2019 General $1,529 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Koroscil
  • Hospitalist median
  • Middle half of Hospitalist
  • National median

In program year 2025, general payments to Thomas Koroscil were reported at $0. Among 6,882 Hospitalist profiles paid that year, the median was $86 and the middle half received between $30 and $191.

Show as a table
Year Thomas Koroscil Hospitalist median Middle half National median
2019 $1,529 $96 $28–$201 $163
2020 $433 $48 $19–$125 $114
2021 $1,196 $70 $23–$167 $132
2022 $587 $85 $27–$174 $149
2023 $261 $89 $30–$191 $160
2024 $0 $95 $29–$204 $164
2025 $0 $86 $30–$191 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Amgen Inc. $1,467 14 payments
  2. Abbott Laboratories $511 5 payments
  3. Corcept Therapeutics $322 14 payments
  4. Sanofi-Aventis U.S. LLC $285 4 payments
  5. Lilly USA, LLC $167 11 payments
  6. Novo Nordisk Inc $140 10 payments
  7. Astellas Pharma US Inc $129 1 payment
  8. Allergan Inc. $125 1 payment
  9. AbbVie, Inc. $122 1 payment
  10. Shire North American Group Inc $122 1 payment
  11. Other $616 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $4,005 88 payments
Products named General payments · program years 2019–2023
  1. EVENITY $583 6 payments
  2. Korlym $322 14 payments
  3. FreeStyle Libre 2 $268 3 payments
  4. Prolia $241 3 payments
  5. Repatha $241 2 payments
  6. AIMOVIG $228 2 payments
  7. Otezla $190 2 payments
  8. SOLIQUA 100/33 $190 2 payments
  9. JARDIANCE $143 9 payments
  10. FreeStyle Libre Pro $129 1 payment
  11. Other $1,651 74 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

81

Median for Hospitalist: 109

Drug cost

$448

Median for Hospitalist: $6,399

Branded share of claims

0%

Median for Hospitalist: 19.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Levothyroxine Sodium Generic 35 $237
Pioglitazone Hcl Generic 13 $107
Metoprolol Succinate Generic 14 $67
Prednisone Generic 19 $37

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,498 Part D prescribers listed as Hospitalist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$22,160

Medicare's payments for the services billed

Medicare patients

121

Average age 76

Services billed

272

61 women, 60 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Ischemic heart disease 56%
Heart failure 55%
Chronic kidney disease 48%
Depression 48%
Diabetes 46%
COPD 45%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

88 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record